Commercial APIs | PG API

Glaucoma

Latanoprost
Antiglaucoma


Bimatoprost
Antiglaucoma


Travoprost
Antiglaucoma


Tafluprost
Antiglaucoma

Blood Circulation

Beraprost Sodium
Antithrombotic


Limaprost Alfadex 3%
Vasodilator,
Lumbar spinal stenosis

Alprostadil
Vasodilator


PAH

Epoprostenol Sodium
Pulmonary arterial
hypertension

Iloprost
Pulmonary arterial
hypertension

Treprostinil Sodium
Pulmonary arterial
hypertension

Obstetrics

Misoprostol HPMC 1%
Antiulcer,
Labor induction

Dinoprostone
Oxytocic abortifacient





Veterinary Prostaglandins

Synchronization of Oestrus, Reproductive disorders associated with persistent corpus luteum,
Termination of unwanted pregnancy (cattle), Induction of parturition (cattle, pigs)

Commercial APIs

Ophthalmology

Bromfenac Sodium
Ophthalmic topical NSAID


Lifitegrast
Dry eye disease

Skeletal Muscle Relaxant

Atracurium Besylate
Skeletal muscle relaxant


Cisatracurium Besylate
Skeletal muscle relaxant

Anti-Parkinson’s Disease

Cabergoline
Alzheimer disease,
Hyperprolactinemic disorders

Pramipexole HCl
Parkinson's disease,
Restless leg syndrome

Anti-Viral

Entecavir
Hepatitis B infection


Miscellaneous

Eldecalcitol
Osteoporosis

Lubiprostone
Chronic constipation

Nalfurafine HCl
Pruritus in
Hemodialysis patients

Sugammadex Sodium
Reversal of
neuromuscular blockade

R&D APIs

Alfacalidol
Osteoporosis
(Vitamin D Derivative)

Latanoprostene Bunod
Antiglaucoma


Naloxegol Oxalate
Opioid-induced
constipation

Relugolix
Prostate cancer,
Uterine fibroids

Atogepant
Migraine


Lenvatinib Mesylate
Thyroid cancer


Netasudil Dimesylate
Antiglaucoma


Suvorexant
Insomnia

Empagliflozin
Type 2 diabetes


Methylphenidate Hydrochloride
Attention-deficit/
Hyperactivity disorder

Paricalcitol
Secondary Hyperparathyroidism
(Vitamin D Derivative)

Teneligliptin Hydrobromide
Type 2 diabetes

Eribulin Mesylate
Metastatic Breast Cancer


Naldemedine Tosylate
Opioid-induced
constipation

Ripasudil hydrochloride hydrate
Glaucoma
Ocular hypertension

Ubrogepant
Migraine

Finished Dosage Forms (Commercial)

Product Name

Formulation

Strength

Therapeutic Area

Status

Latanoprost

Eye drop solution
0,2 ml Single Unit Does,
Box of 30 & 90 Unit SUD’s

50 mcg/ml



Glaucoma &
Ocular Hypertension


EU CTD Available



Latanoprost

Formulation:
Eye drop solution
0,2 ml Single Unit Does,
Box of 30 & 90 Unit SUD’s

Strength:
50 mcg/ml



Therapeutic Area:
Glaucoma & Ocular Hypertension

Status:
EU CTD Available

Iloprost

Formulation:
Sol. Inj.
1 ml, 2.5 ml amp.
0.5 ml, 1 ml amp.

Strength:
20 mcg/ml
100 mcg/ml

Therapeutic Area:
Peripheral Arterial Occlusive Disease (PAOD)

Status:
EU CTD Available

Iloprost

Formulation:
Nebulizer Sol.
1 ml, 2 ml amp.
1 ml amp.

Strength:
10 mcg/ml
20 mcg/ml

Therapeutic Area:
Pulmanory Arterial Hypertension (PAH)

Status:
EU CTD Available

Iloprost

Sol. Inj.
1 ml, 2.5 ml amp.
0.5 ml, 1 ml amp.

20 mcg/ml
100 mcg/ml


Peripheral Arterial Occlusive Disease (PAOD)


EU CTD Available



Iloprost

Nebulizer Sol.
1 ml, 2 ml amp.
1 ml amp.

10 mcg/ml
20 mcg/ml


Pulmanory Arterial Hypertension (PAH)


EU CTD Available



Finished Dosage Forms (R&D)

Product Name

Formulation

Strength

Therapeutic Area

Status

Bimatoprost

Eye drop solution
0,2 ml Single Unit Does,
Box of 30 Unit SUD’s

100 mcg/ml



Glaucoma &
Ocular Hypertension


Available soon



Bimatoprost

Formulation:
Eye drop solution
0,2 ml Single Unit Does,
Box of 30 Unit SUD’s

Strength:
100 mcg/ml



Therapeutic Area:
Glaucoma &
Ocular Hypertension

Status:
Available soon


Tafluprost

Formulation:
Eye drop solution
0,2 ml Single Unit Does,
Box of 30 Unit SUD’s

Strength:
15 mcg/ml


Therapeutic Area:
Glaucoma &
Ocular Hypertension

Status:
Available soon


Tafluprost

Eye drop solution
0,2 ml Single Unit Does,
Box of 30 Unit SUD’s

15 mcg/ml



Glaucoma &
Ocular Hypertension


Available soon